CHICAGO — Novo Nordisk’s next-generation weight problems injection focusing on the amylin hormone confirmed substantial weight reduction in an early research, however related efficacy throughout totally different doses and excessive charges of negative effects increase questions on which dose Novo will pursue going ahead.
Within the Part 1/2 research testing the drug, referred to as amycretin, sufferers on the very best dose of 60 mg misplaced on common 24.3% of their weight at 36 weeks, whereas these on placebo misplaced 1.1%, in line with outcomes printed Friday within the Lancet that may also be introduced on the American Diabetes Affiliation convention. These outcomes recommend amycretin may very well be simpler than different medication available on the market.
In one other a part of the research testing 20-mg, 5-mg, and 1.25-mg doses of amycretin, sufferers additionally skilled substantial weight reduction, however with overlapping weight-loss curves. The discovering is uncommon since researchers usually anticipate a dose-dependent impact, the place sufferers on increased doses lose extra weight sooner.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.